Brodalumab significantly improves Depression in Psoriasis Patients

A recent study published in The Journal of Dermatology found a promising treatment avenue for individuals battling psoriasis alongside the often accompanying emotional burden of depression and anxiety. The study by Ylva Andersch-Björkman and team evaluated the emotional well-being of psoriatic patients who had undergone a treatment switch from tumor necrosis factor-alpha inhibition (TNF-α) to interleukin 17 inhibition using brodalumab due to insufficient responses. 

Psoriasis is a chronic skin condition that often comes with emotional tolls such as depression and anxiety. Managing these mental health aspects alongside the physical symptoms of psoriasis is crucial for overall patient well-being.

The study, conducted over a span of 3 months, included 20 patients with psoriasis. To gauge the emotional impact of the transition to brodalumab treatment, researchers employed the Self-rated Montgomery-Asberg Depression Rating Scale and the Hospital Anxiety and Depression Scale. The results were nothing short of remarkable.

First and foremost, the study reported a significant improvement in the Psoriasis Area and Severity Index (PASI) scores, indicating a tangible reduction in psoriatic lesions and severity. However, what truly captivated the researchers was the substantial improvement in symptoms of depression.

While anxiety symptoms showed a reduction, they did not reach statistical significance, hinting at a potential avenue for further research. Nevertheless, the newfound positive effects on depression and anxiety seemed to operate independently of the reduction in psoriatic lesions. This suggests that the treatment might possess a unique quality in addressing the emotional aspects of psoriasis.

These findings underscore the importance of holistic patient care when dealing with psoriasis. Psoriasis isn't just skin deep; it affects the emotional and psychological well-being of patients. Brodalumab, with its potential to alleviate both physical and emotional symptoms, could revolutionize psoriasis management.

Reference:

Andersch‐Björkman, Y., Micu, E., Seifert, O., Lonne‐Rahm, S., Gillstedt, M., & Osmancevic, A. (2023). Effects of brodalumab on psoriasis and depressive symptoms in patients with insufficient response to TNF‐α inhibitors. In The Journal of Dermatology. Wiley. https://doi.org/10.1111/1346-8138.16917